search
Back to results

Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Lipovirtide for injection
Sponsored by
Shanxi Kangbao Biological Product Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 18~60 years old (including the critical value), male and female are not limited.
  2. Body mass index BMI [weight (kg)/height2 (m2)] is 18.0~28.0 (including the critical value), male weight should be ≥50kg, female weight should be ≥45kg.
  3. Diagnosed with HIV-1 infection.
  4. Those who did not plan to have children within 2 weeks prior to screening and within 3 months after the end of the trial and who agreed to use effective non-pharmacological contraception during the trial.
  5. Subjects should fully understand the purpose, nature and methods of the test and the possible adverse effects and voluntarily participate in this test.

Exclusion Criteria:

Subjects meeting any of the following criteria will not be allowed to enter the trial

  1. The presence of any of the following 1)Unexplained persistent irregular fever of 38°C or more for >1 month. 2)Diarrhea (stools more than 3 times/day), >1 month. 3)Weight loss of 10% or more within 6 months. 4)Recurrent oral fungal infections. 5)Recurrent herpes simplex virus infection or herpes zoster virus infection. 6)Pneumocystis carinii pneumonia (PCP). 7)Recurrent bacterial pneumonia. 8)Active tuberculosis or non-tuberculous mycobacteriosis. 9)Deep fungal infection. 10)Occupational lesions of the central nervous system. 11)Dementia in young and middle-aged adults. 12)Active cytomegalovirus (CMV) infection. 13)Toxoplasma encephalopathy. 14)Malnefield basket disease. 15)Recurrent sepsis. 16)Kaposi's sarcoma, lymphoma.
  2. Patients who have received antiviral therapy and/or HIV vaccination;
  3. HBsAg of (+), and/or anti-HCV of (+);
  4. Abnormal liver function (ALT/AST>3XULN, or TBIL>2XULN);
  5. Creatinine clearance<70mL/min (Equation of calculation: Cockcroft-Gault)
  6. Existing severe chronic disease, metabolic disease (such as diabetes), neurological and psychiatric disease;
  7. History of pancreatitis;
  8. Regnant, lactating women and women of childbearing age who cannot use contraception as required;
  9. People with allergies or known allergies to the ingredients of this medicine;
  10. People with a history of smoking within 12 months before screening (the average number of cigarettes smoked per day is 35.);
  11. People with a history of alcoholism within 12 months before screening(Drink N14 units of alcohol per week on average: 1 unit = 285mL of beer, or 25mL of spirits, or 150mL of wine) or positive alcohol breath test before enrollment;
  12. People with have a history of drug abuse within 12 months before screening or those who tested positive for addictive substances before enrollment;
  13. Participated in other drug trials within 3 months before screening;
  14. The investigator believes that the subject has other conditions that are not suitable for participating in the trial.

Sites / Locations

  • Beijing You'an Hospital, Beijing Medical University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Dose 5 mg

Dose 20 mg

Dose 40 mg

Arm Description

Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.

Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.

Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.

Outcomes

Primary Outcome Measures

Changes from baseline in respiration rate of Vital Signs.
Respiration rate in times / minute
Changes from baseline in Blood lactate of Laboratory Examination.
Changes of blood lactate will be recorded.
Changes from baseline in Pregnancy test of Laboratory Examination.
Pregnancy test will be tested in female subjects.
Changes from baseline in Drug resistance test of Laboratory Examination.
Changes of drug resistance test will be recorded.Evaluate the proportion of HIV resistance in subjects.
Changes from baseline in Immunogenic blood collection of Laboratory Examination.
Changes of immunogenic blood collection will be recorded.The historical changes of test results (including positive rate and titer) of various indicators were counted.
Changes from baseline in blood pressure of Vital Signs.
Blood pressure in mmHg
Changes from baseline in body temperature of Vital Signs.
Body temperature in Celsius degree
Changes from baseline in red blood cell count of Laboratory Examination.
Red blood cell count in whole blood is reported in the form of number.
Changes from baseline in white blood cell count of Laboratory Examination.
White blood cell count in whole blood is reported in the form of number.
Changes from baseline in neutrophil count of Laboratory Examination.
Neutrophil count in whole blood is reported in the form of number.
Changes from baseline in lymphocyte count of Laboratory Examination.
Lymphocyte count in whole blood is reported in the form of number.
Changes from baseline in platelet count of Laboratory Examination.
Platelet count in whole blood is reported in the form of number.
Changes from baseline in hemoglobin of Laboratory Examination.
Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.
Changes from baseline in PT of Laboratory Examination.
Prothrombin time (PT) is a screening test for exogenous coagulation factors.
Changes from baseline in INR of Laboratory Examination.
International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.
Changes from baseline in APTT of Laboratory Examination.
Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.
Changes from baseline in total bilirubin of Laboratory Examination.
Changes of total bilirubin concentration (μmol/L) in serum will be recorded.
Changes from baseline in direct bilirubin of Laboratory Examination.
Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.
Changes from baseline in ALT of Laboratory Examination.
Changes of ALT concentration (U/L) in serum will be recorded.
Changes from baseline in AST of Laboratory Examination.
Changes of AST concentration (U/L) in serum will be recorded.
Changes from baseline in total protein of Laboratory Examination.
Changes of total protein concentration (g/L) in serum will be recorded.
Changes from baseline in albumin of Laboratory Examination.
Changes of albumin concentration (g/L) in serum will be recorded.
Changes from baseline in total bile acid of Laboratory Examination
Changes of total bile acid concentration (μmol/L) in serum will be recorded.
Changes from baseline in urea of Laboratory Examination.
Changes of urea concentration (mmol/L) in serum will be recorded.
Changes from baseline in creatinine of Laboratory Examination.
Changes of creatinine concentration (μmol/L) in serum will be recorded.
Changes from baseline in uric acid of Laboratory Examination.
Changes of uric acid concentration (μmol/L) in serum will be recorded.
Changes from baseline in glucose of Laboratory Examination
Changes of glucose concentration (mmol/L) in serum will be recorded.
Changes from baseline in potassium of Laboratory Examination.
Changes of potassium concentration (mmol/L) in serum will be recorded.
Changes from baseline in sodium of Laboratory Examination.
Changes of sodium concentration (mmol/L) in serum will be recorded.
Changes from baseline in chlorine of Laboratory Examination.
Changes of chlorine concentration (mmol/L) in serum will be recorded.
Changes from baseline in urine specific gravity of Laboratory Examination.
Changes of urine specific gravity will be recorded.
Changes from baseline in urine pH of Laboratory Examination.
Changes of urine pH value will be recorded.
Changes from baseline in urine glucose of Laboratory Examination.
Changes of urine glucose will be examined by qualitative test (positive or negative).
Changes from baseline in urine protein of Laboratory Examination.
Changes of urine protein will be examined by qualitative test (positive or negative).
Changes from baseline in urine ketone body of Laboratory Examination.
Changes of urine ketone body will be examined by qualitative test (positive or negative).
Changes from baseline in urine white blood cell of Laboratory Examination.
Changes of white blood cell in urine will be examined by qualitative test (positive or negative).
Changes from baseline in urine bilirubin of Laboratory Examination.
Changes of urine bilirubin will be examined by qualitative test (positive or negative).
Changes from baseline in urine occult blood of Laboratory Examination.
Changes of urine occult blood will be examined by qualitative test (positive or negative).
Changes from baseline in Electrocardiogram.
The cardiac rhythm is showed in electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded,To evaluate the incidence of abnormal electrocardiogram.
Changes from baseline in CK of Laboratory Examination
Changes of CK concentration (U/L) in serum will be recorded.
Changes from baseline in CK-MB of Laboratory Examination
Changes of CK-MB concentration (ng/mL) in serum will be recorded.
Changes from baseline in LDH of Laboratory Examination
Changes of LDH concentration (U/L) in serum will be recorded.
Changes from baseline in ALP of Laboratory Examination
Changes of ALP concentration (U/L) in serum will be recorded.
Changes from baseline in Triglyceride of Laboratory Examination
Changes of Triglyceride concentration (mmol/L) in serum will be recorded.
Changes from baseline in CHOL of Laboratory Examination
Changes of CHOL concentration (mmol/L) in serum will be recorded.
Changes from baseline in TP of Laboratory Examination
Changes of TP concentration (g/L) in serum will be recorded.
Changes from baseline in ALB of Laboratory Examination
Changes of ALB concentration (g/L) in serum will be recorded.
Changes from baseline in UA of Laboratory Examination
Changes of UA concentration (μmol/L) in serum will be recorded.
Changes from baseline in GLU of Laboratory Examination
Changes of GLU concentration (mmol/L) in serum will be recorded.
Changes from baseline in AMY of Laboratory Examination
Changes of AMY concentration (U/L) in serum will be recorded.

Secondary Outcome Measures

Changes from baseline in HIV viral load detection of Laboratory Examination.
Changes of HIV viral load detection will be recorded.
Changes from baseline in CD4+T cell counts of Laboratory Examination.
Changes of CD4+T cell counts will be recorded.
Incidence of anti-Lipovetin antibody.
Incidence of anti-Lipovetin antibody.

Full Information

First Posted
April 2, 2022
Last Updated
September 17, 2023
Sponsor
Shanxi Kangbao Biological Product Co., Ltd.
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT05349968
Brief Title
Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients
Official Title
A Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients Who Have Not Received Antiretroviral Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
June 10, 2022 (Actual)
Primary Completion Date
June 7, 2023 (Actual)
Study Completion Date
September 7, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanxi Kangbao Biological Product Co., Ltd.
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objectives 1.Evaluation of safety and tolerability after repeated administration of injectable Lipivirtide in HIV-infected patients not receiving antiretroviral therapy Secondary Objectives Evaluation of the pharmacokinetic properties of injectable Lipovirtide after multiple administrations in HIV-infected patients not receiving antiretroviral therapy, to obtain pharmacokinetic parameters. Evaluation of the efficacy of injectable Lipovirtide for HIV in HIV-infected patients not receiving antiretroviral therapy. Evaluation of the immunogenicity of lipovirtide for injection.
Detailed Description
PK parameters were calculated by Phoenix WinNonlin 8.2 (or higher) and other data were analyzed using SAS 9.4 (or higher) software. Full analysis set: will be used for efficacy analysis. Descriptive statistics of HIV viral load and CD4+ T-cell count at each time point, calculation of subject means, standard deviations, quartiles, minimum and maximum values, and comparison of changes from baseline at each time point. Safety analysis set: calculation of the incidence of adverse events and systematic categorization. Calculate the incidence of adverse events and systematically categorize them. Cross tabulation of clinical determination before and after drug administration for laboratory tests, ECG tests, and physical examination. Changes in measured values of vital signs over time. The actual measured values of the vital signs varied over time. Immunogenicity analysis: statistics of the results of each indicators (including the positive incidence and titer) over time, and a detailed list of the results of each visit. Pharmacokinetic analysis: individual and mean c-t curves were plotted; mean, standard deviation, interquartile, maximum, minimum and coefficient of variation of blood concentrations at each time point were listed. Pharmacokinetic parameters were calculated for each subject from the non-compartment model. and the arithmetic mean, standard deviation, quartiles, maximum value, minimum value and geometric mean and coefficient of variation were also calculated for each parameter.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dose 5 mg
Arm Type
Experimental
Arm Description
Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
Arm Title
Dose 20 mg
Arm Type
Experimental
Arm Description
Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
Arm Title
Dose 40 mg
Arm Type
Experimental
Arm Description
Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
Intervention Type
Drug
Intervention Name(s)
Lipovirtide for injection
Other Intervention Name(s)
nothing
Intervention Description
Multiple dosing of Lipovirtide
Primary Outcome Measure Information:
Title
Changes from baseline in respiration rate of Vital Signs.
Description
Respiration rate in times / minute
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in Blood lactate of Laboratory Examination.
Description
Changes of blood lactate will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in Pregnancy test of Laboratory Examination.
Description
Pregnancy test will be tested in female subjects.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in Drug resistance test of Laboratory Examination.
Description
Changes of drug resistance test will be recorded.Evaluate the proportion of HIV resistance in subjects.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in Immunogenic blood collection of Laboratory Examination.
Description
Changes of immunogenic blood collection will be recorded.The historical changes of test results (including positive rate and titer) of various indicators were counted.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in blood pressure of Vital Signs.
Description
Blood pressure in mmHg
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in body temperature of Vital Signs.
Description
Body temperature in Celsius degree
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in red blood cell count of Laboratory Examination.
Description
Red blood cell count in whole blood is reported in the form of number.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in white blood cell count of Laboratory Examination.
Description
White blood cell count in whole blood is reported in the form of number.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in neutrophil count of Laboratory Examination.
Description
Neutrophil count in whole blood is reported in the form of number.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in lymphocyte count of Laboratory Examination.
Description
Lymphocyte count in whole blood is reported in the form of number.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in platelet count of Laboratory Examination.
Description
Platelet count in whole blood is reported in the form of number.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in hemoglobin of Laboratory Examination.
Description
Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in PT of Laboratory Examination.
Description
Prothrombin time (PT) is a screening test for exogenous coagulation factors.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in INR of Laboratory Examination.
Description
International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in APTT of Laboratory Examination.
Description
Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in total bilirubin of Laboratory Examination.
Description
Changes of total bilirubin concentration (μmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in direct bilirubin of Laboratory Examination.
Description
Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in ALT of Laboratory Examination.
Description
Changes of ALT concentration (U/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in AST of Laboratory Examination.
Description
Changes of AST concentration (U/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in total protein of Laboratory Examination.
Description
Changes of total protein concentration (g/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in albumin of Laboratory Examination.
Description
Changes of albumin concentration (g/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in total bile acid of Laboratory Examination
Description
Changes of total bile acid concentration (μmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urea of Laboratory Examination.
Description
Changes of urea concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in creatinine of Laboratory Examination.
Description
Changes of creatinine concentration (μmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in uric acid of Laboratory Examination.
Description
Changes of uric acid concentration (μmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in glucose of Laboratory Examination
Description
Changes of glucose concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in potassium of Laboratory Examination.
Description
Changes of potassium concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in sodium of Laboratory Examination.
Description
Changes of sodium concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in chlorine of Laboratory Examination.
Description
Changes of chlorine concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine specific gravity of Laboratory Examination.
Description
Changes of urine specific gravity will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine pH of Laboratory Examination.
Description
Changes of urine pH value will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine glucose of Laboratory Examination.
Description
Changes of urine glucose will be examined by qualitative test (positive or negative).
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine protein of Laboratory Examination.
Description
Changes of urine protein will be examined by qualitative test (positive or negative).
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine ketone body of Laboratory Examination.
Description
Changes of urine ketone body will be examined by qualitative test (positive or negative).
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine white blood cell of Laboratory Examination.
Description
Changes of white blood cell in urine will be examined by qualitative test (positive or negative).
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine bilirubin of Laboratory Examination.
Description
Changes of urine bilirubin will be examined by qualitative test (positive or negative).
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in urine occult blood of Laboratory Examination.
Description
Changes of urine occult blood will be examined by qualitative test (positive or negative).
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in Electrocardiogram.
Description
The cardiac rhythm is showed in electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded,To evaluate the incidence of abnormal electrocardiogram.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in CK of Laboratory Examination
Description
Changes of CK concentration (U/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in CK-MB of Laboratory Examination
Description
Changes of CK-MB concentration (ng/mL) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in LDH of Laboratory Examination
Description
Changes of LDH concentration (U/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in ALP of Laboratory Examination
Description
Changes of ALP concentration (U/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in Triglyceride of Laboratory Examination
Description
Changes of Triglyceride concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in CHOL of Laboratory Examination
Description
Changes of CHOL concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in TP of Laboratory Examination
Description
Changes of TP concentration (g/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in ALB of Laboratory Examination
Description
Changes of ALB concentration (g/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in UA of Laboratory Examination
Description
Changes of UA concentration (μmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in GLU of Laboratory Examination
Description
Changes of GLU concentration (mmol/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in AMY of Laboratory Examination
Description
Changes of AMY concentration (U/L) in serum will be recorded.
Time Frame
Within 50 days after the first administration.
Secondary Outcome Measure Information:
Title
Changes from baseline in HIV viral load detection of Laboratory Examination.
Description
Changes of HIV viral load detection will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Changes from baseline in CD4+T cell counts of Laboratory Examination.
Description
Changes of CD4+T cell counts will be recorded.
Time Frame
Within 50 days after the first administration.
Title
Incidence of anti-Lipovetin antibody.
Description
Incidence of anti-Lipovetin antibody.
Time Frame
Within 50 days after the first administration.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18~60 years old (including the critical value), male and female are not limited. Body mass index BMI [weight (kg)/height2 (m2)] is 18.0~28.0 (including the critical value), male weight should be ≥50kg, female weight should be ≥45kg. Diagnosed with HIV-1 infection. Those who did not plan to have children within 2 weeks prior to screening and within 3 months after the end of the trial and who agreed to use effective non-pharmacological contraception during the trial. Subjects should fully understand the purpose, nature and methods of the test and the possible adverse effects and voluntarily participate in this test. Exclusion Criteria: Subjects meeting any of the following criteria will not be allowed to enter the trial The presence of any of the following 1)Unexplained persistent irregular fever of 38°C or more for >1 month. 2)Diarrhea (stools more than 3 times/day), >1 month. 3)Weight loss of 10% or more within 6 months. 4)Recurrent oral fungal infections. 5)Recurrent herpes simplex virus infection or herpes zoster virus infection. 6)Pneumocystis carinii pneumonia (PCP). 7)Recurrent bacterial pneumonia. 8)Active tuberculosis or non-tuberculous mycobacteriosis. 9)Deep fungal infection. 10)Occupational lesions of the central nervous system. 11)Dementia in young and middle-aged adults. 12)Active cytomegalovirus (CMV) infection. 13)Toxoplasma encephalopathy. 14)Malnefield basket disease. 15)Recurrent sepsis. 16)Kaposi's sarcoma, lymphoma. Patients who have received antiviral therapy and/or HIV vaccination; HBsAg of (+), and/or anti-HCV of (+); Abnormal liver function (ALT/AST>3XULN, or TBIL>2XULN); Creatinine clearance<70mL/min (Equation of calculation: Cockcroft-Gault) Existing severe chronic disease, metabolic disease (such as diabetes), neurological and psychiatric disease; History of pancreatitis; Regnant, lactating women and women of childbearing age who cannot use contraception as required; People with allergies or known allergies to the ingredients of this medicine; People with a history of smoking within 12 months before screening (the average number of cigarettes smoked per day is 35.); People with a history of alcoholism within 12 months before screening(Drink N14 units of alcohol per week on average: 1 unit = 285mL of beer, or 25mL of spirits, or 150mL of wine) or positive alcohol breath test before enrollment; People with have a history of drug abuse within 12 months before screening or those who tested positive for addictive substances before enrollment; Participated in other drug trials within 3 months before screening; The investigator believes that the subject has other conditions that are not suitable for participating in the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Haibin Yu
Organizational Affiliation
Beijing You'an Hospital, Beijing Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hao Wu
Organizational Affiliation
Beijing You'an Hospital, Beijing Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing You'an Hospital, Beijing Medical University
City
Beijing
Country
China

12. IPD Sharing Statement

Learn more about this trial

Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients

We'll reach out to this number within 24 hrs